iSAM Funds UK Ltd Raises Stock Position in Johnson & Johnson $JNJ

iSAM Funds UK Ltd lifted its stake in Johnson & Johnson (NYSE:JNJ) by 474.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 25,013 shares of the company’s stock after buying an additional 20,655 shares during the quarter. Johnson & Johnson accounts for 0.8% of iSAM Funds UK Ltd’s portfolio, making the stock its 12th biggest position. iSAM Funds UK Ltd’s holdings in Johnson & Johnson were worth $3,821,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GFG Capital LLC purchased a new stake in Johnson & Johnson in the second quarter worth about $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $48,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Johnson & Johnson by 66.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 376 shares of the company’s stock valued at $57,000 after purchasing an additional 150 shares during the period. Finally, Clal Insurance Enterprises Holdings Ltd lifted its stake in shares of Johnson & Johnson by 390.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 392 shares of the company’s stock valued at $65,000 after purchasing an additional 312 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on JNJ. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a report on Monday, October 6th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Citigroup upped their price objective on shares of Johnson & Johnson from $213.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, October 15th. Finally, UBS Group lifted their target price on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a report on Tuesday, October 14th. Four analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $203.15.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $201.51 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a market capitalization of $485.50 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a one year low of $140.68 and a one year high of $207.81. The company’s 50-day moving average is $194.45 and its 200 day moving average is $175.90.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.